Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 16, 2021

SELL
$38.07 - $56.17 $342,439 - $505,249
-8,995 Closed
0 $0
Q1 2021

May 12, 2021

SELL
$32.41 - $70.91 $2.18 Million - $4.77 Million
-67,305 Reduced 88.21%
8,995 $457,000
Q4 2020

Feb 16, 2021

BUY
$31.02 - $35.16 $2.37 Million - $2.68 Million
76,300 New
76,300 $2.6 Million

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $59.2M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track Pura Vida Investments, LLC Portfolio

Follow Pura Vida Investments, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pura Vida Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pura Vida Investments, LLC with notifications on news.